Clostridium difficile infection: new developments in epidemiology and pathogenesis
The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Abstract
Clostridium difficile is now considered to be one of the most important causes of health care-associated infections. C. difficile infections are also emerging in the community and in animals used for food, and are no longer viewed simply as unpleasant complications that follow antibiotic therapy. Since 2001, the prevalence and severity of C. difficile infection has increased significantly, which has led to increased research interest and the discovery of new virulence factors, and has expanded and focused the development of new treatment and prevention regimens. This Review summarizes the recent epidemiological changes in C. difficile infection, our current knowledge of C. difficile virulence factors and the clinical outcomes of C. difficile infection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, studies have demonstrated that patients suffering from recurrent CDI are deficient in phyla of bacteria normally dominant in the colon6,45 (Figure 1).”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [45]
Citations
Cites
Dethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060280 · Cited by 2,361 · cited 1×
“It is becoming evident from 16S ribosomal RNA sequencing that disruption of the gut microbiota following antibiotic treatment is much greater than was previously realize”
BackgroundAn Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Kazakova, S. V., Sambol, S. P., Johnson, S., & Gerding, D. N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051590 · Cited by 2,006
Loo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,946
Interventions to improve antibiotic prescribing practices for hospital inpatients
Davey, P., Brown, E., Charani, E., Fenelon, L., Gould, I. M., Holmes, A., Ramsay, C. R., Wiffen, P. J., & Wilcox, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003543.pub3 · Cited by 1,864
Nosocomial Acquisition of Clostridium difficile Infection
McFarland, L. V., Mulligan, M. E., Kwok, R. Y. Y., & Stamm, W. E. (1989) · New England Journal of Medicine · doi:10.1056/nejm198901263200402 · Cited by 1,326
Zar, F. A., Bakkanagari, S. R., Moorthi, K. M. L. S. T., & Davis, M. B. (2007) · Clinical Infectious Diseases · doi:10.1086/519265 · Cited by 1,252
Pepin, J. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041104 · Cited by 1,128
Glucosylation of Rho proteins by Clostridium difficile toxin B
Just, I., Selzer, J., Wilm, M., Eichel-Streiber, C. V., Mann, M., & Aktories, K. (1995) · Nature · doi:10.1038/375500a0 · Cited by 1,032
Decreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/525047 · Cited by 1,010
Pepin, J., Saheb, N., Coulombe, M.-A., Alary, M.-E., Corriveau, M.-P., Authier, S., Leblanc, M., Rivard, G., Bettez, M., Primeau, V., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/496986 · Cited by 995
Research works printed but not linked: 5
- Summary points on quarterly (October to December. 2008) and financial year (2007/08) acute Trust Clostridium difficile data. Key points: analyses of quarterly mandatory Clostridium difficile surveillance data. Health Protection Agency [online] , (2008).
- Thompson, A. et al. in Ninth Biennial Congress of the Anaerobe Society of Americas. PII-14 (Long Beach, California, 2008).
- Angulo, F. et al. in Second International Clostridium difficile Symposium. P5 (Maribor, Slovenia, 2007).
- Louie, T. et al. in The 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. K-425a (Chicago, Illinois, 2007).
- Merrigan, M. M., Gerding, D. N. & Vedantam, G. in Eighth Biennial Conference of the Anaerobe Society of America. PI-12 (Boise, Idaho, 2006).
Cited by
Role of the gut microbiota in immunity and inflammatory disease
Kamada, N., Seo, S.-U., Chen, G. Y., & Núñez, G. (2013) · Nature reviews. Immunology · doi:10.1038/nri3430 · Cited by 2,256
Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile
Buffie, C. G., Bucci, V., Stein, R. R., McKenney, P. T., Ling, L., Gobourne, A., No, D., Liu, H., Kinnebrew, M., Viale, A., et al. (2015) · Nature · doi:10.1038/nature13828 · Cited by 1,872
Control of pathogens and pathobionts by the gut microbiota
Kamada, N., Chen, G. Y., Inohara, N., & Núñez, G. (2013) · Nature Immunology · doi:10.1038/ni.2608 · Cited by 1,625
Proton pump inhibitors affect the gut microbiome
Imhann, F., Bonder, M. J., Vich Vila, A., Fu, J., Mujagic, Z., Vork, L., Tigchelaar, E. F., Jankipersadsing, S. A., Cenit, M. C., Harmsen, H. J. M., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310376 · Cited by 1,371
Host Biology in Light of the Microbiome: Ten Principles of Holobionts and Hologenomes
Bordenstein, S. R., & Theis, K. R. (2015) · PLOS Biology · doi:10.1371/journal.pbio.1002226 · Cited by 1,240
Consequences of bile salt biotransformations by intestinal bacteria
Ridlon, J. M., Harris, S. C., Bhowmik, S., Kang, D.-J., & Hylemon, P. B. (2016) · Gut Microbes · doi:10.1080/19490976.2015.1127483 · Cited by 1,100
Th17 and regulatory T cells in mediating and restraining inflammation
Littman, D. R., & Rudensky, A. Y. (2010) · Cell · doi:10.1016/j.cell.2010.02.021 · Cited by 1,039
Clostridium difficile infection in Europe: a hospital-based survey
Bauer, M. P., Notermans, D. W., van Benthem, B. H., Brazier, J. S., Wilcox, M. H., Rupnik, M., Monnet, D. L., van Dissel, J. T., & Kuijper, E. J. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61266-4 · Cited by 1,020
Treating Clostridium difficile infection with fecal microbiota transplantation
Bakken, J. S., Borody, T., Brandt, L. J., Brill, J. V., Demarco, D. C., Franzos, M. A., Kelly, C., Khoruts, A., Louie, T., Martinelli, L. P., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.08.014 · Cited by 1,003
Antibiotics and the Human Gut Microbiome: Dysbioses and Accumulation of Resistances
Francino, M. P. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.01543 · Cited by 945
“…aureus and, of most concern, Clostridium difficile, which can cause intractable, long-term recurrent infections and even a potentially lethal pseudomembranous colitis (Wilcox, 2003; Young and Schmidt, 2004; Song et al., 2008; Rupnik et al., 2009; Sekirov et al., 2010; Chen et al., 2013).”
BackgroundBezlotoxumab for Prevention of Recurrent Clostridium difficile Infection
Wilcox, M. H., Gerding, D. N., Poxton, I. R., Kelly, C., Nathan, R., Birch, T., Cornely, O. A., Rahav, G., Bouza, E., Lee, C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1602615 · Cited by 858
The intestinal microbiota: Antibiotics, colonization resistance, and enteric pathogens
Kim, S., Covington, A., & Pamer, E. G. (2017) · Immunological Reviews · doi:10.1111/imr.12563 · Cited by 741
Hamilton, M. J., Weingarden, A. R., Sadowsky, M. J., & Khoruts, A. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.482 · Cited by 738
The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism
Spanogiannopoulos, P., Bess, E. N., Carmody, R. N., & Turnbaugh, P. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.17 · Cited by 717
Relating the metatranscriptome and metagenome of the human gut
Franzosa, E. A., Morgan, X. C., Segata, N., Waldron, L., Reyes, J., Earl, A. M., Giannoukos, G., Boylan, M. R., Ciulla, D., Gevers, D., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319284111 · Cited by 704
Bacteriocin Production: a Probiotic Trait?
Dobson, A., Cotter, P. D., Ross, R. P., & Hill, C. (2012) · Applied and Environmental Microbiology · doi:10.1128/aem.05576-11 · Cited by 687
Fecal microbiota transplantation and emerging applications
Borody, T. J., & Khoruts, A. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.244 · Cited by 677
“difficile strains with increased virulence, such as PCR ribotype 027/North American Pulsed-field type 1 (NAP1), which is characterized by resistance to fluoroquinolones and increased toxin production attributable to a mutation in tcdC , as well as binary toxin production”
BackgroundYoungster, I., Russell, G. H., Pindar, C., Ziv-Baran, T., Sauk, J., & Hohmann, E. L. (2014) · JAMA · doi:10.1001/jama.2014.13875 · Cited by 629
“3) [11-89] 3 (3-5) [2-6] 10 (8-15) [6-30] 5 (5-7) [2-9] 4.”
Buffie, C. G., Jarchum, I., Equinda, M., Lipuma, L., Gobourne, A., Viale, A., Ubeda, C., Xavier, J., & Pamer, E. G. (2012) · Infection and Immunity · doi:10.1128/iai.05496-11 · Cited by 596
“Clostridium difficile is a Gram-positive, anaerobic, spore-forming bacterium that primarily causes infections in hospitalized patients and residents of long-term health care facilities (29, 31).”
BackgroundOverdiagnosis of Clostridium difficile Infection in the Molecular Test Era
Polage, C. R., Gyorke, C. E., Kennedy, M. A., Leslie, J. L., Chin, D. L., Wang, S., Nguyen, H. H., Huang, B., Tang, Y.-W., Lee, L. W., et al. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.4114 · Cited by 593
“Duration of metronidazole or oral vancomycin, if treated, median (IQR), d 14 (11-14) 6 (3-11) 5 (2-9) <.”
BackgroundInfluentialImportance of prophages to evolution and virulence of bacterial pathogens
Fortier, L.-C., & Sekulovic, O. (2013) · Virulence · doi:10.4161/viru.24498 · Cited by 577
Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook
Kelly, C. R., Kahn, S., Kashyap, P., Laine, L., Rubin, D., Atreja, A., Moore, T., & Wu, G. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.008 · Cited by 572
Role of the Commensal Microbiota in Normal and Pathogenic Host Immune Responses
Littman, D. R., & Pamer, E. G. (2011) · Cell Host & Microbe · doi:10.1016/j.chom.2011.10.004 · Cited by 556
“C. difficile is acquired by the oral ingestion of spores from a contaminated environment (Rupnik et al., 2009).”
BackgroundInfluentialIntestinal colonization resistance
Lawley, T. D., & Walker, A. W. (2013) · Immunology · doi:10.1111/j.1365-2567.2012.03616.x · Cited by 610
Youngster, I., Sauk, J., Pindar, C., Wilson, R. G., Kaplan, J. L., Smith, M. B., Alm, E. J., Gevers, D., Russell, G. H., & Hohmann, E. L. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu135 · Cited by 467
“The emergence of a virulent strain of the organism (NAP1/BI/027) has been associated with even higher rates of treatment failure [9,10].”
BackgroundClostridium difficile spore biology: sporulation, germination, and spore structural proteins
Paredes-Sabja, D., Shen, A., & Sorg, J. A. (2014) · Trends in Microbiology · doi:10.1016/j.tim.2014.04.003 · Cited by 419
“The clinical symptoms are caused by the secretion of two large toxins, the enterotoxin TcdA and the cytotoxin TcdB, which cause massive damage to the epithelium and induce strong inflammatory responses [1].”
BackgroundEpidemiology of Community-Associated Clostridium difficile Infection, 2009 Through 2011
Chitnis, A. S., Holzbauer, S. M., Belflower, R. M., Winston, L. G., Bamberg, W. M., Lyons, C., Farley, M. M., Dumyati, G. K., Wilson, L. E., Beldavs, Z. G., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.7056 · Cited by 405
“Age, median (range), y 53 (1-93) 48 (1-97) 53 (1-94) .”
Can we identify patients at high risk of recurrent Clostridium difficile infection?
Kelly, C. P. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12046 · Cited by 396
“difficile is resistant to many commonly used antibiotics, with the exception of those used to treat CDI [18].”
BackgroundTernan, N. G., Moore, N. D., Smyth, D., McDougall, G. J., Allwood, J. W., Verrall, S., Gill, C. I. R., Dooley, J. S. G., & McMullan, G. (2018) · Scientific Reports · doi:10.1038/s41598-018-35050-x · Cited by 377
Antibiotic prescribing in hospitals: a social and behavioural scientific approach
Hulscher, M. E., Grol, R. P., & van der Meer, J. W. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70027-x · Cited by 362
Antibiotics, microbiota, and immune defense
Ubeda, C., & Pamer, E. G. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.05.003 · Cited by 356
Liévin-Le Moal, V., & Servin, A. L. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00080-13 · Cited by 354
“difficile produces a number of putative virulence factors, including two members of the large clostridial cytotoxin family, known as toxin A and toxin B, both of which induce intense colonic inflammation and dramatic structural and functional epithelial tissue damage followed by a rapid fluid loss into the intestinal…”
BackgroundClostridium difficile infection: epidemiology, risk factors and management
Ananthakrishnan, A. N. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.190 · Cited by 352
Antimicrobial activity of photocatalysts: Fundamentals, mechanisms, kinetics and recent advances
Ganguly, P., Byrne, C., Breen, A., & Pillai, S. C. (2018) · Applied Catalysis B: Environmental · doi:10.1016/j.apcatb.2017.11.018 · Cited by 351
Eastwood, K., Else, P., Charlett, A., & Wilcox, M. (2009) · Journal of Clinical Microbiology · doi:10.1128/jcm.01082-09 · Cited by 330
“The incidence of C. difficile infection has increased markedly in many countries, notably associated with the epidemic spread of PCR ribotype 027 (NAP1) since its recognition in the United States and Canada (6, 7, 13).”
BackgroundAbou Chakra, C. N., Pepin, J., Sirard, S., & Valiquette, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098400 · Cited by 328
“St e w ar t 2 0 1 3 [3 7 ] P C R to xi n o ty p in g /r ib o ty p in g”
BackgroundInfluentialPereira, F. C., Wasmund, K., Cobankovic, I., Jehmlich, N., Herbold, C. W., Lee, K. S., Sziranyi, B., Vesely, C., Decker, T., Stocker, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18928-1 · Cited by 317
Microbiome therapeutics — Advances and challenges
Mimee, M., Citorik, R. J., & Lu, T. K. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.032 · Cited by 317
“Ablation of the gut microbiota through broad-spectrumantibiotics predisposes individuals to opportunistic pathogens, including Clostridium difficile, that are normally kept at bay by commensal microbes [59].”
Hamilton, M. J., Weingarden, A. R., Unno, T., Khoruts, A., & Sadowsky, M. J. (2013) · Gut Microbes · doi:10.4161/gmic.23571 · Cited by 315
“This is reflected in the increased frequency of diagnosis for both community- and hospital-acquired cases, identification of increasingly hypervirulent strains, greater resistance to antibiotics, higher rates of recurrence and greater prevalence of complications that include toxic megacolon, colectomy and overall mort…”
BackgroundMicrobiota, Inflammation and Colorectal Cancer
Lucas, C., Barnich, N., & Nguyen, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061310 · Cited by 313
“It has been shown that antibiotic-treated mice have increased susceptibility to infection with enteric pathogens compared to untreated mice [99,100].”
BackgroundAntibiotic use and microbiome function
Ferrer, M., Méndez-García, C., Rojo, D., Barbas, C., & Moya, A. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.09.007 · Cited by 299
Abt, M. C., Lewis, B. B., Caballero, S., Xiong, H., Carter, R. A., Sušac, B., Ling, L., Leiner, I., & Pamer, E. G. (2015) · Cell Host & Microbe · doi:10.1016/j.chom.2015.06.011 · Cited by 294
“C. difficile establishes infection following disruption of the indigenous microbiota, usually the result of preceding antibiotic treatment (Rupnik et al., 2009; Viswanathan et al., 2010).”
BackgroundMethodInfluentialMultiple Factors Modulate Biofilm Formation by the Anaerobic Pathogen Clostridium difficile
Thapa, T., Leuzzi, R., Ng, Y. K., Baban, S. T., Adamo, R., Kuehne, S. A., Scarselli, M., Minton, N. P., Serruto, D., & Unnikrishnan, M. (2013) · Journal of Bacteriology · doi:10.1128/jb.01980-12 · Cited by 291
“matory conditions, including pseudomembranous colitis (8).”
Mechanism of the Gut Microbiota Colonization Resistance and Enteric Pathogen Infection
Khan, I., Bai, Y., Zha, L., Ullah, N., Ullah, H., Shah, S. R. H., Sun, H., & Zhang, C. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.716299 · Cited by 291
“difficile and VRE has been found as a leading cause of diarrhea and colitis among healthcare-associated infections (Rupnik et al., 2009; Arias and Murray, 2012), and a specific bacterial population has also been recognized with the clearance and eradication of C.”
BackgroundInfluentialDiversity and Evolution in the Genome of Clostridium difficile
Knight, D. R., Elliott, B., Chang, B. J., Perkins, T. T., & Riley, T. V. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00127-14 · Cited by 286
“RT078 and RT027 strains have been isolated from pork, beef, and chickens in the Northern Hemisphere, with recovery rates varying from 3% in Europe to 42% in North America (201, 202).”
BackgroundHost-microbiome interactions and recent progress into understanding the biology of acne vulgaris
O’Neill, A. M., & Gallo, R. L. (2018) · Microbiome · doi:10.1186/s40168-018-0558-5 · Cited by 334
Infectious diarrhea: Cellular and molecular mechanisms
Hodges, K., & Gill, R. (2010) · Gut Microbes · doi:10.4161/gmic.1.1.11036 · Cited by 281
Frizzled proteins are colonic epithelial receptors for C. difficile toxin B
Tao, L., Zhang, J., Meraner, P., Tovaglieri, A., Wu, X., Gerhard, R., Zhang, X., Stallcup, W. B., Miao, J., He, X., et al. (2016) · Nature · doi:10.1038/nature19799 · Cited by 279
Dietary zinc alters the microbiota and decreases resistance to Clostridium difficile infection
Zackular, J. P., Moore, J. L., Jordan, A. T., Juttukonda, L. J., Noto, M. J., Nicholson, M. R., Crews, J. D., Semler, M. W., Zhang, Y., Ware, L. B., et al. (2016) · Nature Medicine · doi:10.1038/nm.4174 · Cited by 275
Ageing and gut microbes: Perspectives for health maintenance and longevity
Biagi, E., Candela, M., Turroni, S., Garagnani, P., Franceschi, C., & Brigidi, P. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2012.10.005 · Cited by 276
Geiger, T. L., Abt, M. C., Gasteiger, G., Firth, M. A., O’Connor, M. H., Geary, C. D., O’Sullivan, T. E., van den Brink, M. R., Pamer, E. G., Hanash, A. M., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20140212 · Cited by 269
“…is an opportunistic gram-positive bacterium that can cause severe colitis and diarrhea when the normal microbiota is disrupted after antibiotic treatment (Rupnik et al., 2009), and the incidence of infection in hospital settings is increasing, especially among BMT patients (Kelly and LaMont, 2008).”
BackgroundFeazel, L. M., Malhotra, A., Perencevich, E. N., Kaboli, P., Diekema, D. J., & Schweizer, M. L. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku046 · Cited by 269
Zhang, Y., Zhang, L., Yang, L., Vong, C. I., Chan, K. F., Wu, W. K. K., Kwong, T. N. Y., Lo, N. W. S., Ip, M., Wong, S. H., et al. (2019) · Science Advances · doi:10.1126/sciadv.aau9650 · Cited by 257
Di Bella, S., Ascenzi, P., Siarakas, S., Petrosillo, N., & Di Masi, A. (2016) · Toxins · doi:10.3390/toxins8050134 · Cited by 248
“difficile enters a vegetative state, begins to spread, and starts to secrete TcdA and TcdB [13].”
BackgroundMicrobiota-mediated inflammation and antimicrobial defense in the intestine
Caballero, S., & Pamer, E. G. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120238 · Cited by 238
Li, C., Harmanus, C., Zhu, D., Meng, X., Wang, S., Duan, J., Liu, S., Fu, C., Zhou, P., Liu, R., et al. (2018) · Emerging Microbes & Infections · doi:10.1038/s41426-018-0211-1 · Cited by 245
Epidemiology of Clostridium difficile Infection
DePestel, D. D., & Aronoff, D. M. (2013) · Journal of Pharmacy Practice · doi:10.1177/0897190013499521 · Cited by 244
“Several microbial characteristics have been attributed to possible hypervirulence, including mutations in the regulatory gene tcdC causing hyperproduction of toxins A and B, production of a binary toxin, antibiotic resistance, improved toxin binding to target cells, increased sporulation, and mutations in surface laye…”
BackgroundThanissery, R., Winston, J. A., & Theriot, C. M. (2017) · Anaerobe · doi:10.1016/j.anaerobe.2017.03.004 · Cited by 242
“Other PCR ribotypes such as 001, 053, and 106 have also been associated with outbreaks and severe cases [6].”
BackgroundKnetsch, C. W., Connor, T. R., Mutreja, A., van Dorp, S. M., Sanders, I. M., Browne, H. P., Harris, D., Lipman, L., Keessen, E. C., Corver, J., et al. (2014) · Eurosurveillance · doi:10.2807/1560-7917.es2014.19.45.20954 · Cited by 236
“difficile produces highly resistant and infectious spores, which can survive in the environment for a long time and facilitate environmental transmission within the healthcare setting [17].”
Biology of Clostridium difficile: Implications for Epidemiology and Diagnosis
Karen C., C., & John G., B. (2011) · Annual Review of Microbiology · doi:10.1146/annurev-micro-090110-102824 · Cited by 233
“The two toxin genes, tcdA and tcdB, are closely aligned, separated by an intervening sequence (tcdE), and both are transcribed in the same direction (138). tcdE encodes a holin, a protein whose pore-forming activity allows the release of TcdA and TcdB from the cell (40, 138). tcdR, found upstream of tcdB, is a major p…”
BackgroundInfluentialGlobal Analysis of the Sporulation Pathway of Clostridium difficile
Fimlaid, K. A., Bond, J. P., Schutz, K. C., Putnam, E. E., Leung, J. M., Lawley, T. D., & Shen, A. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003660 · Cited by 232
Transmission of the gut microbiota: spreading of health
Browne, H. P., Neville, B. A., Forster, S. C., & Lawley, T. D. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.50 · Cited by 232
Isothiocyanates: An Overview of Their Antimicrobial Activity against Human Infections
Romeo, L., Iori, R., Rollin, P., Bramanti, P., & Mazzon, E. (2018) · Molecules · doi:10.3390/molecules23030624 · Cited by 230
“Ingestion of contaminated food, dietary factors and the imbalance of intestinal microflora induced by antibiotic therapy [77,78] can cause Clostridium infections [79,80].”
BackgroundRea, M. C., O'Sullivan, O., Shanahan, F., O'Toole, P. W., Stanton, C., Ross, R. P., & Hill, C. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.05176-11 · Cited by 222
“difficile infection is primarily regarded as a nosocomial or health care-related disease that is most prominent among the elderly population (29).”
BackgroundInfluentialMicrobial endocrinology: Host-microbiota neuroendocrine interactions influencing brain and behavior
Lyte, M. (2014) · Gut Microbes · doi:10.4161/gmic.28682 · Cited by 217
Horizontal gene transfer in human pathogens
Juhas, M. (2015) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2013.804031 · Cited by 222
“difficile causing a wide variety of potentially deadly gastrointestinal diseases (Jasni et al., 2010; Kachrimanidou & Malisiovas, 2011; Rupnik et al., 2009) has been once regarded as relatively rare but is nowadays considered to be one of the most important causes of nosocomial infections.”
BackgroundConsequences of Clostridium difficile infection: understanding the healthcare burden
Bouza, E. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12064 · Cited by 220
“These include a marked increase in infection rates in younger populations [4], increasing severity of disease accompanied by increases in morbidity and mortality [7,8], and infection in patients who would not previously have been considered to be at risk [5].”
BackgroundFecal microbiota transplantation in relapsing Clostridium difficile infection
Rohlke, F., & Stollman, N. (2012) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x12453637 · Cited by 211
“2006], and in 2010, incidence was estimated at 500,000/year, with mortality rates up to 20,000 cases a year [Heinlen and Ballard, 2010; Rupnik et al. 2009].”
BackgroundVedantam, G., Clark, A., Chu, M., McQuade, R., Mallozzi, M., & Viswanathan, V. K. (2012) · Gut Microbes · doi:10.4161/gmic.19399 · Cited by 209
Asymptomatic Clostridium difficile colonization: epidemiology and clinical implications
Furuya-Kanamori, L., Marquess, J., Yakob, L., Riley, T. V., Paterson, D. L., Foster, N. F., Huber, C. A., & Clements, A. C. A. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-1258-4 · Cited by 207
“difficile infection (CDI) ranges from mild diarrhea to severe complications such as pseudomembranous colitis, toxic megacolon, bowel perforation, sepsis, and death [5].”
BackgroundKang, J. D., Myers, C. J., Harris, S. C., Kakiyama, G., Lee, I.-K., Yun, B.-S., Matsuzaki, K., Furukawa, M., Min, H.-K., Bajaj, J. S., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.10.003 · Cited by 204
“Clostridium difficile, the cause of antibiotic associated diarrhea and colitis, is a growing health threat for patients taking broad spectrum antibiotics (Rupnik et al., 2009).”
BackgroundMicroevolutionary analysis of Clostridium difficile genomes to investigate transmission
Didelot, X., Eyre, D. W., Cule, M., Ip, C. L., Ansari, M. A., Griffiths, D., Vaughan, A., O'Connor, L., Golubchik, T., Batty, E. M., et al. (2012) · Genome Biology · doi:10.1186/gb-2012-13-12-r118 · Cited by 198
“difficile forms resistant spores that can survive either within a patient or in the environment for months or even years [2], during which evolution is effectively suspended.”
Studer, N., Desharnais, L., Beutler, M., Brugiroux, S., Terrazos, M. A., Menin, L., Schürch, C. M., McCoy, K. D., Kuehne, S. A., Minton, N. P., et al. (2016) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2016.00191 · Cited by 195
“The best-studied example is Clostridium difficile infection (CDI), a nosocomial, antibiotic therapy-associated diarrheal infection (Rupnik et al., 2009).”
BackgroundThe influence of proton pump inhibitors and other commonly used medication on the gut microbiota
Imhann, F., Vich Vila, A., Bonder, M. J., Lopez Manosalva, A. G., Koonen, D. P. Y., Fu, J., Wijmenga, C., Zhernakova, A., & Weersma, R. K. (2017) · Gut Microbes · doi:10.1080/19490976.2017.1284732 · Cited by 192
“Awell-known example of reduced enteric infection resistance through alteration of the gut microbiota caused by medication is the increased risk of Clostridium difficile infections after (repeated) treatment with antibiotics.(16) Antibiotics kill off a large proportion of the gut microbiota, creating an empty niche tha…”
BackgroundRousseau, C., Poilane, I., De Pontual, L., Maherault, A.-C., Le Monnier, A., & Collignon, A. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis637 · Cited by 196
Papatheodorou, P., Carette, J. E., Bell, G. W., Schwan, C., Guttenberg, G., Brummelkamp, T. R., & Aktories, K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109772108 · Cited by 190
Theriot, C. M., Koumpouras, C. C., Carlson, P. E., Bergin, I. I., Aronoff, D. M., & Young, V. B. (2011) · Gut Microbes · doi:10.4161/gmic.19142 · Cited by 188
“The clinical picture that results from human infection with C. difficile ranges from asymptomatic colonization to fulminant colitis.25 Chronic, recurrent infection is becoming an increasingly important problem.26 This wide range of disease manifestations is presumed to reflect differences in the host, the indigenous m…”
BackgroundInfluentialDysbiosis of Fungal Microbiota in the Intestinal Mucosa of Patients with Colorectal Adenomas
Luan, C., Xie, L., Yang, X., Miao, H., Lv, N., Zhang, R., Xiao, X., Hu, Y., Liu, Y., Wu, N., et al. (2015) · Scientific Reports · doi:10.1038/srep07980 · Cited by 190
Disease-associated genotypes of the commensal skin bacterium Staphylococcus epidermidis
Méric, G., Mageiros, L., Pensar, J., Laabei, M., Yahara, K., Pascoe, B., Kittiwan, N., Tadee, P., Post, V., Lamble, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07368-7 · Cited by 189
Hasegawa, M., Yamazaki, T., Kamada, N., Tawaratsumida, K., Kim, Y.-G., Núñez, G., & Inohara, N. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003761 · Cited by 186
“difficile disease in humans causes multiple organ dysfunction, sepsis, and even death (1).”
BackgroundInfluentialProbiotics and gastrointestinal disease: successes, problems and future prospects
Culligan, E. P., Hill, C., & Sleator, R. D. (2009) · Gut Pathogens · doi:10.1186/1757-4749-1-19 · Cited by 187
“(iv) Clostridium difficile is a major cause of nosocomial infection with symptoms ranging from mild diarrhea to severe pseudmembranous enterocolitis, sepsis and death [11].”
BackgroundHigh-throughput analysis of gene essentiality and sporulation in Clostridium difficile
Dembek, M., Barquist, L., Boinett, C. J., Cain, A. K., Mayho, M., Lawley, T. D., Fairweather, N. F., & Fagan, R. P. (2015) · mBio · doi:10.1128/mbio.02383-14 · Cited by 185
From Stool Transplants to Next-Generation Microbiota Therapeutics
Petrof, E. O., & Khoruts, A. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.01.004 · Cited by 186
Cowardin, C. A., Buonomo, E. L., Saleh, M. M., Wilson, M. G., Burgess, S. L., Kuehne, S. A., Schwan, C., Eichhoff, A. M., Koch-Nolte, F., Lyras, D., et al. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.108 · Cited by 185
Horizontal gene transfer converts non-toxigenic Clostridium difficile strains into toxin producers
Brouwer, M. S. M., Roberts, A. P., Hussain, H., Williams, R. J., Allan, E., & Mullany, P. (2013) · Nature Communications · doi:10.1038/ncomms3601 · Cited by 181
Davies, K. A., Ashwin, H., Longshaw, C. M., Burns, D. A., Davis, G. L., Wilcox, M. H., & on behalf of the EUCLID study group (2016) · Eurosurveillance · doi:10.2807/1560-7917.es.2016.21.29.30294 · Cited by 181
Clostridium difficile infection and antibiotic-associated diarrhoea
Mullish, B. H., & Williams, H. R. (2018) · Clinical Medicine · doi:10.7861/clinmedicine.18-3-237 · Cited by 182
Chamberlain, R., & Lau, C. (2016) · International Journal of General Medicine · doi:10.2147/ijgm.s98280 · Cited by 177
“difficile was first described by Hall and O’Toole(23) as part of the intestinal microflora in neonates, and represents the leading cause of AAD.(24,25) Prior to the year 2000, the rate of CDI in the USA did not vary greatly from year to year and has been relatively stable at 30–40 cases per 100,000 population.”
BackgroundFischer, M., Kao, D., Kelly, C., Kuchipudi, A., Jafri, S.-M., Blumenkehl, M., Rex, D., Mellow, M., Kaur, N., Sokol, H., et al. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000908 · Cited by 178
Ng, Y. K., Ehsaan, M., Philip, S., Collery, M. M., Janoir, C., Collignon, A., Cartman, S. T., & Minton, N. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056051 · Cited by 175
“fulminant, relapsing and potentially fatal colitis [1,2].”
Clostridium difficile – From Colonization to Infection
Schäffler, H., & Breitrück, A. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00646 · Cited by 174
“While C. difficile is an anaerobic organism, C. difficile spores can survive in aerobic environments for months or years (Rupnik et al., 2009).”
BackgroundInfluentialPathogenic role of the gut microbiota in gastrointestinal diseases
Nagao-Kitamoto, H., Kitamoto, S., Kuffa, P., & Kamada, N. (2016) · Intestinal Research · doi:10.5217/ir.2016.14.2.127 · Cited by 172
Dynamics and Establishment of Clostridium difficile Infection in the Murine Gastrointestinal Tract
Koenigsknecht, M. J., Theriot, C. M., Bergin, I. L., Schumacher, C. A., Schloss, P. D., & Young, V. B. (2015) · Infection and Immunity · doi:10.1128/iai.02768-14 · Cited by 171
“difficile exhibit clinical manifestations that can range from mild diarrhea to toxic megacolon and death (2).”
BackgroundClostridium difficile Toxins: Mediators of Inflammation
Shen, A. (2012) · Journal of Innate Immunity · doi:10.1159/000332946 · Cited by 171
Maclean, M., McKenzie, K., Anderson, J. G., Gettinby, G., & MacGregor, S. J. (2014) · Journal of Hospital Infection · doi:10.1016/j.jhin.2014.06.004 · Cited by 167
Clinical Clostridium difficile: Clonality and Pathogenicity Locus Diversity
Dingle, K. E., Griffiths, D., Didelot, X., Evans, J., Vaughan, A., Kachrimanidou, M., Stoesser, N., Jolley, K. A., Golubchik, T., Harding, R. M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019993 · Cited by 165
“Individuals may be asymptomatically colonised in the community, or acquire the bacteria nosocomially [2].”
BackgroundAnti-infective properties of bacteriocins: an update
Hammami, R., Fernandez, B., Lacroix, C., & Fliss, I. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1202-3 · Cited by 165
“difficile infection [108].”
Clostridium difficile and One Health
Lim, S. C., Knight, D. R., & Riley, T. V. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2019.10.023 · Cited by 165
The Spore Differentiation Pathway in the Enteric Pathogen Clostridium difficile
Pereira, F. C., Saujet, L., Tomé, A. R., Serrano, M., Monot, M., Couture-Tosi, E., Martin-Verstraete, I., Dupuy, B., & Henriques, A. O. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003782 · Cited by 162
“difficile is now both a main nosocomial pathogen associated with antibiotic therapy as well as a major concern in the community [8], [9], [14].”
BackgroundInfluentialSpecimen Collection, Transport, and Processing: Bacteriology
Baron, E. J. (2015) · Manual of Clinical Microbiology · doi:10.1128/9781555817381.ch18 · Cited by 159
Metadata
- Authors
- Rupnik, M., Wilcox, M. H., & Gerding, D. N.
- Affiliations
- University of Maribor (SI)
- Leeds General Infirmary (GB)
- Loyola University Chicago (US)
- Venue
- Nature Reviews Microbiology
- Published
- 2009-07
- Volume
- 7
- Issue
- 7
- Pages
- 526-536
- ISSN
- 1740-1526 (ISSN-L)
- 1740-1534
- OpenAlex
- W1968953113
- Cited by
- 1,380
- References
- 124
- Citations by year
- 2026: 18 · 2025: 36 · 2024: 49 · 2023: 59 · 2022: 74 · 2021: 72 · 2020: 88 · 2019: 78 · 2018: 109 · 2017: 104 · 2016: 107 · 2015: 107 · 2014: 133 · 2013: 141 · 2012: 93
- FWCI
- 8.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Microbiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Health Sciences › Medicine › Infectious Diseases › Infection Control in Healthcare
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Keywords
- Clostridium difficile infection, nosocomial infections, virulence factors, epidemiology, pathogenesis, community-acquired infections, food-producing animals, antibiotic-associated diarrhea, clinical outcomes, infection prevention and treatment
- MeSH terms
- Animals, Anti-Bacterial Agents, Enterocolitis, Pseudomembranous, Humans, Models, Theoretical, Clostridioides difficile, Virulence Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.